aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of aTyr Pharma (NASDAQ:ATYR) to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, aTyr Pharma currently has a consensus rating of “Moderate Buy”.

aTyr Pharma Stock Up 27.3%

ATYR stock opened at $6.29 on Friday. aTyr Pharma has a 52-week low of $4.07 and a 52-week high of $44.40. The stock’s fifty day simple moving average is $12.94 and its 200-day simple moving average is $24.03. The stock has a market capitalization of $15.42 million, a price-to-earnings ratio of -0.25 and a beta of 0.91.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Friday, August 7th. The company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.86) by $0.46. As a group, analysts anticipate that aTyr Pharma will post -17.80 earnings per share for the current fiscal year.

Institutional Trading of aTyr Pharma

An institutional investor recently raised its stake in aTyr Pharma stock. Bank of America Corp DE boosted its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 303,559 shares of the company’s stock after buying an additional 176,859 shares during the period. Bank of America Corp DE owned approximately 0.31% of aTyr Pharma worth $237,000 at the end of the most recent reporting period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.